Fever After Influenza, Diphtheria-Tetanus-Acellular Pertussis, and Pneumococcal Vaccinations.
Journal
Pediatrics
ISSN: 1098-4275
Titre abrégé: Pediatrics
Pays: United States
ID NLM: 0376422
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
accepted:
27
11
2019
pubmed:
8
2
2020
medline:
15
5
2020
entrez:
8
2
2020
Statut:
ppublish
Résumé
Administering inactivated influenza vaccine (IIV), 13-valent pneumococcal conjugate vaccine (PCV13), and diphtheria-tetanus-acellular pertussis (DTaP) vaccine together has been associated with increased risk for febrile seizure after vaccination. We assessed the effect of administering IIV at a separate visit from PCV13 and DTaP on postvaccination fever. In 2017-2018, children aged 12 to 16 months were randomly assigned to receive study vaccines simultaneously or sequentially. They had 2 study visits 2 weeks apart; nonstudy vaccines were permitted at visit 1. The simultaneous group received PCV13, DTaP, and quadrivalent IIV (IIV4) at visit 1 and no vaccines at visit 2. The sequential group received PCV13 and DTaP at visit 1 and IIV4 at visit 2. Participants were monitored for fever (≥38°C) and antipyretic use during the 8 days after visits. There were 110 children randomly assigned to the simultaneous group and 111 children to the sequential group; 90% received ≥1 nonstudy vaccine at visit 1. Similar proportions of children experienced fever on days 1 to 2 after visits 1 and 2 combined (simultaneous [8.1%] versus sequential [9.3%]; adjusted relative risk = 0.87 [95% confidence interval 0.36-2.10]). During days 1 to 2 after visit 1, more children in the simultaneous group received antipyretics (37.4% vs 22.4%; In our study, delaying IIV4 administration by 2 weeks in children receiving DTaP and PCV13 did not reduce fever occurrence after vaccination. Reevaluating this strategy to prevent fever using an IIV4 with a different composition in a future influenza season may be considered.
Sections du résumé
BACKGROUND
Administering inactivated influenza vaccine (IIV), 13-valent pneumococcal conjugate vaccine (PCV13), and diphtheria-tetanus-acellular pertussis (DTaP) vaccine together has been associated with increased risk for febrile seizure after vaccination. We assessed the effect of administering IIV at a separate visit from PCV13 and DTaP on postvaccination fever.
METHODS
In 2017-2018, children aged 12 to 16 months were randomly assigned to receive study vaccines simultaneously or sequentially. They had 2 study visits 2 weeks apart; nonstudy vaccines were permitted at visit 1. The simultaneous group received PCV13, DTaP, and quadrivalent IIV (IIV4) at visit 1 and no vaccines at visit 2. The sequential group received PCV13 and DTaP at visit 1 and IIV4 at visit 2. Participants were monitored for fever (≥38°C) and antipyretic use during the 8 days after visits.
RESULTS
There were 110 children randomly assigned to the simultaneous group and 111 children to the sequential group; 90% received ≥1 nonstudy vaccine at visit 1. Similar proportions of children experienced fever on days 1 to 2 after visits 1 and 2 combined (simultaneous [8.1%] versus sequential [9.3%]; adjusted relative risk = 0.87 [95% confidence interval 0.36-2.10]). During days 1 to 2 after visit 1, more children in the simultaneous group received antipyretics (37.4% vs 22.4%;
CONCLUSIONS
In our study, delaying IIV4 administration by 2 weeks in children receiving DTaP and PCV13 did not reduce fever occurrence after vaccination. Reevaluating this strategy to prevent fever using an IIV4 with a different composition in a future influenza season may be considered.
Identifiants
pubmed: 32029684
pii: peds.2019-1909
doi: 10.1542/peds.2019-1909
pmc: PMC7055925
pii:
doi:
Substances chimiques
13-valent pneumococcal vaccine
0
Diphtheria-Tetanus-acellular Pertussis Vaccines
0
Influenza Vaccines
0
Pneumococcal Vaccines
0
Banques de données
ClinicalTrials.gov
['NCT03165981']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2020 by the American Academy of Pediatrics.
Déclaration de conflit d'intérêts
POTENTIAL CONFLICT OF INTEREST: Dr Klein reports potential conflicts due to support received from GlaxoSmithKline, Sanofi Pasteur, Pfizer, Merck, Protein Science (now Sanofi Pasteur), Dynavax, and MedImmune; the other authors have indicated they have no potential conflicts of interest to disclose.
Références
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Pediatrics. 2016 Jul;138(1):
pubmed: 27273711
Vaccine. 2012 Mar 2;30(11):2024-31
pubmed: 22361304
MMWR Morb Mortal Wkly Rep. 2017 Feb 10;66(5):134-135
pubmed: 28182607
Expert Rev Vaccines. 2005 Jun;4(3):419-27
pubmed: 16026253
Pediatrics. 2005 Apr;115(4):1039-47
pubmed: 15805382
JAMA Pediatr. 2014 Mar;168(3):211-9
pubmed: 24395025
N Engl J Med. 2001 Aug 30;345(9):656-61
pubmed: 11547719
Vaccine. 2012 Oct 5;30(45):6461-71
pubmed: 22917957
Pharmacoepidemiol Drug Saf. 2016 Aug;25(8):928-34
pubmed: 27037540
Drugs Context. 2018 Jul 16;7:212536
pubmed: 30038660
Vaccine. 2012 Dec 17;31(1):271-7
pubmed: 22835735